Provided by Tiger Trade Technology Pte. Ltd.

Benitec Biopharma

11.02
-0.3400-2.99%
Post-market: 11.020.00000.00%16:14 EDT
Volume:422.99K
Turnover:4.67M
Market Cap:384.41M
PE:-11.26
High:11.62
Open:11.37
Low:10.86
Close:11.36
52wk High:16.76
52wk Low:9.85
Shares:34.88M
Float Shares:18.45M
Volume Ratio:3.07
T/O Rate:2.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9783
EPS(LYR):-0.9800
ROE:-33.21%
ROA:-22.67%
PB:2.17
PE(LYR):-11.24

Loading ...

BNTC: BB-301 Clinical Progress and Strong Cash Position Drive Ritu Baral’s Buy Rating

TIPRANKS
·
Sep 16

Benitec Biopharma price target raised to $17 from $16 at Wedbush

TIPRANKS
·
Sep 15

Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), CVS Health (CVS) and BioNTech SE (BNTX)

TIPRANKS
·
Sep 15

Wedbush Lifts Price Target on Benitec Biopharma to $17 From $16, Keeps Outperform Rating

MT Newswires Live
·
Sep 15

Benitec Biopharma Files $200 Million Shelf Registration

MT Newswires Live
·
Sep 15

Benitec Biopharma files $200M mixed securities shelf

TIPRANKS
·
Sep 15

Benitec Biopharma - May Offer Securities up to $200 Mln - SEC Filing

THOMSON REUTERS
·
Sep 15

Benitec Biopharma Q4 EPS $(0.26), Inline

Benzinga Earnings
·
Sep 15

Benitec Biopharma Publishes Fy2026 Annual Report

Reuters
·
Sep 15

Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update

THOMSON REUTERS
·
Sep 15

Benitec Biopharma Initiated at Outperform by Wedbush

Dow Jones
·
Jul 28

Benitec Biopharma Inc : Wedbush Initiates Coverage with Outperform Rating; Target Price $16

THOMSON REUTERS
·
Jul 28

Wedbush Initiates Benitec Biopharma at Outperform With $16 Price Target

MT Newswires Live
·
Jul 28

Novartis Receives European Commission Approval for Itvisma® for Spinal Muscular Atrophy (SMA)

Reuters
·
Jul 07

Novartis Receives European Commission Approval for Itvisma® for Spinal Muscular Atrophy (SMA)

Reuters
·
Jul 02

Benitec Biopharma downgraded to Neutral from Buy at Guggenheim

TIPRANKS
·
Jun 10

Benitec Biopharma Announces Board Changes and New Director

TIPRANKS
·
May 30

BRIEF-Benitec Biopharma - CFO Megan Boston Resigns From Board Effective May 22, 2026

Reuters
·
May 30

Benitec Biopharma - Megan Boston to Continue as Chief Financial Officer and Secretary - SEC Filing

THOMSON REUTERS
·
May 30

Benitec Biopharma files Form 3 for director David Matthew Friedman

Reuters
·
May 29